Novo Nordisk is working on a new obesity ... past few months as investors fret that demand for weight-loss drugs isn’t as ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians can combine, mix, or adjust the ingredients of a medication — to meet ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk's semaglutide trial showed 62.9% of patients experienced resolution of symptoms with no worsening of scarring. "Novo Nordisk's Weight-Loss Drug Helps Improve Symptoms of Liver Disease, ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...